EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study

Paige Schoenberg, O Winslow Edwards, Leland Merrill, Cristian Acero Martinez, Rob Stephenson iD, Patrick S Sullivan iD, Jeb Jones iD

Journal of the International AIDS Society · 2023-03 · 26 (3)

DOI: 10.1002/jia2.26077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the International AIDS Society, online erschienen am 23.03.2023. Verfasst von Paige Schoenberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Sexual and Gender Minorities, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINR NIH HHS, National Institute of Nursing Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Long‐acting injectable (LAI) pre‐exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrEP. Willingness to use LAI PrEP and preference for LAI versus oral PrEP has not been reported for sexual and gender minority (SGM) people in the southern United States, where the HIV epidemic is concentrated. Our goal was to assess willingness to use LAI PrEP and preference for oral versus LAI PrEP among SGM people in the southern United States and to assess differences in willingness by demographics and sexual behaviour.

Methods

We conducted an online, cross‐sectional survey of SGM people aged 15–34 years in the southern United States ( n = 583). Participants reported willingness to use LAI PrEP and preferences for LAI PrEP versus daily oral PrEP. We assessed bivariate associations and adjusted prevalence ratios for the LAI‐PrEP‐related outcomes and key demographic and behavioural characteristics.

Results

Overall, 68% of all participants ( n = 393) reported being willing to use LAI PrEP that provides protection against HIV for 3 months. Of those, most ( n = 320, 81%) indicated a preference for using LAI PrEP, compared to a daily oral pill or no preference. Willingness to use LAI PrEP was more common among transgender and non‐binary participants and participants who engaged in condomless anal intercourse in the last 6 months. Hispanic participants were more likely and non‐Hispanic Black participants were less likely to report willingness to use LAI PrEP compared to non‐Hispanic White participants.

Conclusions

Willingness to use LAI PrEP was high among SGM people in the southern United States, although there were some important differences in willingness based on demographic characteristics. Decreased willingness to use LAI PrEP among groups who are disproportionately affected by the HIV epidemic, such as non‐Hispanic Black SGM people, could exacerbate existing disparities in HIV incidence. LAI PrEP is an acceptable option among SGM populations in the southern United States, but strategies will be needed to ensure equitable implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsSexual and Gender MinoritiesPre-Exposure ProphylaxisMaleHumansUnited StatesCross-Sectional StudiesHomosexuality, MalePatient Acceptance of Health CareSexual Behavior

Stichwörter der Autor:innen

HIVinjectablemen who have sex with menpre-exposure prophylaxissexual and gender minority populationstransgender people

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Department of Epidemiology, Emory University, Atlanta, Georgia, USA.
  • Department of Systems, Populations and Leadership, School of Nursing and The Center for Sexuality and Health Disparities, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Rob Stephenson, Patrick S Sullivan, Jeb Jones

Förderung

  • NINR NIH HHS
  • National Institute of Nursing Research

Zitieren

APA

Schoenberg, P., Edwards, O. W., Merrill, L., Martinez, C. A., Stephenson, R., Sullivan, P. S., & Jones, J. (2023). Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study. Journal of the International AIDS Society, 26(3). https://doi.org/10.1002/jia2.26077

Vancouver

Schoenberg P, Edwards OW, Merrill L, Martinez CA, Stephenson R, Sullivan PS, et al. Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study. Journal of the International AIDS Society. 2023;26(3). doi:10.1002/jia2.26077

BibTeX
@article{Schoenberg2023,
  author = {Schoenberg, Paige and Edwards, O Winslow and Merrill, Leland and Martinez, Cristian Acero and Stephenson, Rob and Sullivan, Patrick S and Jones, Jeb},
  title = {Willingness to use and preferences for long‐acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study},
  journal = {Journal of the International AIDS Society},
  year = {2023},
  volume = {26},
  number = {3},
  doi = {10.1002/jia2.26077}
}
Kostenlos starten →